Персона: Громушкина, Елена Вячеславовна
Загружается...
Email Address
Birth Date
Научные группы
Организационные подразделения
Организационная единица
Инженерно-физический институт биомедицины
Цель ИФИБ и стратегия развития – это подготовка высококвалифицированных кадров на базе передовых исследований и разработок новых перспективных методов и материалов в области инженерно-физической биомедицины. Занятие лидерских позиций в биомедицинских технологиях XXI века и внедрение их в образовательный процесс, что отвечает решению практикоориентированной задачи мирового уровня – диагностике и терапии на клеточном уровне социально-значимых заболеваний человека.
Статус
Фамилия
Громушкина
Имя
Елена Вячеславовна
Имя
3 results
Результаты поиска
Теперь показываю 1 - 3 из 3
- ПубликацияТолько метаданныеReview of radiation technologies for the treatment of covid-19 coronavirus infection(2021) Gameeva, E. V.; Sarapultseva, E. I.; Garmash, A. A.; Gromushkina, E. V.; Maksarova, D. D.; Сарапульцева, Елена Игоревна; Гармаш, Александр Александрович; Громушкина, Елена Вячеславовна; Максарова, Дарима Дамбаевна© 2021 State Research Center, Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency. All rights reserved.Due to the long-term lack of effective pharmacological concepts, the situation with the spread of a new coronavirus infection in 2019 (COVID-19) has aroused interest in considering the possible use of radiation technologies, including historical reports on the treatment of patients with pneumonia using low-dose radiation therapy. A brief review of articles on clinical trials of radiation technologies in the fight against COVID-19 is conducted. The authors of most of the analyzed articles, as well as the authors of this review, conclude that the available scientific data do not justify clinical trials of low-dose radiation therapy for the treatment of COVID-19 pneumonia due to the unclear benefits and risks of mortality from radiation-induced diseases, including radiogenic cancer and diseases of the circulatory system.
- ПубликацияТолько метаданныеLaser Synthesis of Bismuth Nanoparticles for Multimodal Theranostics of Oncological Diseases(2022) Tikhonowski, G. V.; Popov, A. A.; Kurinnaya, A. A.; Garmash, A. A.; Gromushkina, E. V.; Zavestovskaya, I. N.; Klimentov, S. M.; Klimentov, S.M.; Тихоновский, Глеб Валерьевич; Попов, Антон Александрович; Гармаш, Александр Александрович; Громушкина, Елена Вячеславовна; Климентов, Сергей МихайловичAbstract: The effect of laser radiation parameters on properties of bismuth (Bi) nanoparticles (NPs) produced by pulsed laser ablation in liquids (PLAL) was studied. We demonstrated that the average NPs size increases under the increase of laser radiation energy and the decrease in the distance from the focusing lens to the target surface. The obtained results provide a tool for a controllable synthesis of new functional nanomaterials for biomedical applications. © 2022, Allerton Press, Inc.
- ПубликацияТолько метаданныеQuantitative Assessment of the Quality of Remote Irradiation Planning for Cancer Patients(2022) Lebedenko, I. M.; Kudashkina, Y. A.; Gromushkina, E. V.; Zakharkiv, A. Y.; Лебеденко, Ирина Матвеевна; Громушкина, Елена Вячеславовна; Захаркив, Анастасия ЮрьевнаRelationships between the index HI of dose homogeneity within the target and irradiation technique were obtained for patients with four types of cancer: cervical cancer, lung cancer, prostate cancer, and breast cancer. Homogeneity indexes HI were evaluated. The optimum irradiation techniques were selected for patients with each type of cancer taking account of the prognostic capabilities of the index HI for recurrence-free survival. These studies showed in particular that 3D-conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT) were suitable for treatment of cervical cancer. Intensity-modulated radiotherapy in the rotary mode (RapidArc) had advantages in lung cancer. The RapidArc technique was best in prostate cancer. The 3DCRT technique run on conventional accelerators was preferred in breast cancer. © 2022, Springer Science+Business Media, LLC, part of Springer Nature.